In one of the biggest breakthroughs in schizophrenia research in recent times, Professor Cynthia Shannon Weickert at Neuroscience Research Australia (NeuRA) has identified immune cells in greater amounts in the brains of some people with schizophrenia. The study published today in Molecular Psychiatry has the potential to transform global schizophrenia research and open new avenues for developing targeted immune cell therapies.
One in every 100 Australians lives with schizophrenia. No single cause of schizophrenia has been identified, and this has prevented the development of a cure. The current treatments for schizophrenia are designed to suppress symptoms rather than target underlying causes of the disorder. These drugs only partially relieve symptoms and can produce unwanted side effects.
To recognise the significance of this discovery Professor Shannon Weickert says you first need to understand most scientists have had a long held belief that immune cells were independent from the brain pathology in psychotic illnesses.
“In our study, we challenged this assumption that immune cells were independent of the brain in psychiatric illness and made an exciting discovery. We identified immune cells as a new player in the brain pathology of schizophrenia,” said Professor Shannon Weickert.
Current schizophrenia research has focused on the status of three brain cells: the neurons; the glial cells, which support the neurons; and the endothelial cells, which coat the blood vessels. Employing new molecular techniques allowed Professor Shannon Weickert and her team to identify the presence of a fourth cell, the macrophage, a type of immune cell in the brain tissue of people with schizophrenia who show high levels of inflammation.
Professor Shannon Weickert said immune cells have previously been ignored as they had long been viewed simply as travelers just thought to be passing by, undertaking surveillance work. They have never been a suspect until now.
“To find immune cells along the blood brain barrier in increased amounts in people with schizophrenia is an exciting discovery. It suggests immune cells themselves may be producing these inflammatory signals in the brains of people living with schizophrenia,” said Professor Shannon Weickert.
“We have observed in people with schizophrenia, the glial cells, one of the local residents, become inflamed and produce distress signals which change the status of the endothelial cells.
“We think this may cause the endothelial cells to extend sticky tentacles, so when the immune cells travel by some are captured. These cells may transmigrate across the blood brain barrier entering the brain in greater amounts in some people with schizophrenia compared to people without the disorder.”
This discovery shows that specific immune cells are in the brains of some people with schizophrenia in close enough proximity to the neurons to do damage.
Professor Peter Schofield, CEO of NeuRA said this innovative new research has the ability to alter the way in which we may be able to diagnose and treat schizophrenia.
“This breakthrough demonstrates the value of the NSW Government’s support for Professor Shannon Weickert as NSW Chair of Schizophrenia Research, which has delivered new insights that the community seeks,” said Professor Schofield.
Professor Shannon Weickert is encouraging a cross-collaborative approach between neuroscientists and immunologists globally, to work together to develop treatments targeting this abnormal immune pathology of schizophrenia.
“This opens whole new avenues for therapy, because it suggests that the pathology of schizophrenia could be within the immune cells and the immune cells could be contributing to the symptoms of schizophrenia,” said Professor Shannon Weickert.
Professor Shannon Weickert is uniquely motivated in her work, with her twin-brother being diagnosed with schizophrenia when he was 17 years old.
Learn more: Schizophrenia breakthrough
The Latest on: Schizophrenia
[google_news title=”” keyword=”schizophrenia” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Schizophrenia
- Teva Stock Powers Ahead as Schizophrenia News Offsets Mixed Earningson May 8, 2024 at 11:10 am
Shares of Teva Pharmaceutical Industries were climbing yet again on Wednesday, after the company announced positive results in a trial of a schizophrenia medicine. Its quarterly results, also ...
- Cat owners could be at higher risk of schizophrenia, study suggestson May 8, 2024 at 10:58 am
Snuggling with a cat seems like a loving and relaxing activity, but a new study implies that it might affect your mental health down the line.
- Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higheron May 8, 2024 at 10:49 am
PANSS measures the symptom severity of schizophrenia. TEV-‘749 utilizes SteadyTeq, a copolymer technology proprietary to Medincell that provides a controlled, steady release of olanzapine, the most ...
- How BI humanizes schizophrenia experience in return of popup exhibiton May 8, 2024 at 7:28 am
Boehringer Ingelheim brought its latest iteration of Look Beyond Stable, an immersive exhibit showing how people with schizophrenia live, back to New York.
- Teva Pharmaceutical’s stock climbs as schizophrenia treatment shows promiseon May 8, 2024 at 6:15 am
Teva Pharmaceutical Industries stock jumped more than 6% early Wednesday after the company reported first-quarter sales that topped estimates and released positive late-stage trial data on a ...
- Teva And Medincell Say Phase 3 SOLARIS Study In Schizophrenia Met Primary Goalon May 8, 2024 at 4:43 am
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), and Medincell Wednesday said the Phase 3 ...
- Teva, Medincell's schizophrenia drug succeeds in late-stage studyon May 8, 2024 at 4:25 am
Israel-based Teva Pharmaceuticals , TEVA.N and French partner Medincell said on Wednesday their experimental schizophrenia drug had met its main goal of reducing the severity of symptoms in a ...
- Long-Acting Subcutaneous Olanzapine Effective in Schizophrenia Trialon May 7, 2024 at 5:00 pm
A once-monthly subcutaneous formulation of olanzapine (TEV-’749) was found to improve symptoms in patients with schizophrenia without post injection delirium syndrome (PDSS). Using a proprietary ...
- 'Impressive' New Data on Novel Schizophrenia Hopeful KarXTon May 7, 2024 at 5:00 pm
Results of the EMERGENT-3 trial confirm that the novel investigational antipsychotic xanomeline-trospium (KarXT, Karuna Therapeutics) is effective and well tolerated in adults with schizophrenia ...
via Bing News